Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: Accelerated and Adaptive RT for Locally-Advanced NSCLC
NCT03128008Phase 2Completed
- Sponsor
- Duke University
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and Paclitaxel Micelles for Injection in non-small cell lung cancer (NSCLC), sponsored by Duke University. Primary endpoint: Metabolic Complete Response Rate at 4 weeks. Started Dec 2017; status: completed.
02
Drugs
carboplatinPaclitaxel Micelles for Injection
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03128008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128008.